Resumen

SOLIS-RODRIGUEZ, Marcela; ALPUCHE-SOLIS, Ángel G.  y  TIRADO-MENDOZA, Rocío G.. Human Metapneumovirus: Epidemiology and Possible Prophylactic Treatments. Rev. Fac. Med. (Méx.) [online]. 2020, vol.63, n.3, pp.7-18.  Epub 05-Mar-2021. ISSN 2448-4865.  https://doi.org/10.22201/fm.24484865e.2019.63.3.02.

In 2001 in the Netherlands, Human metapneumovirus (hMPV) was identified as a “new” etiologic agent causing acute respiratory infections in children younger than 5 years old; however, it has also been isolated in the elderly and immunocompromised people. This virus is considered the second etiological agent in acute diseases of the respiratory tract. Currently, the estimated cost of IRAs in our country is of 9,000 USD per inpatient.

hMPV is a member of the genus Metapneumovirus, family Pneumoviridae, and it belongs to the order Mononegavirales that is part of the negative single-stranded ribonucleic acid (RNA) virus, consisting of eight genes ordered: 3’-N-P-M-F-M2-SH-G-L-5 ‘, and which encodes for 9 proteins. Of these proteins, the F fusion glycoprotein is highly conserved in the genus Metapneumovirus, and is the major antigenic determinant, and because an approved vaccine doesn’t exist, it has been used as a candidate epitope for the design of a vaccine that confers host immunity or as a therapeutic target in the creation of antiviral peptides that inhibit the fusion of the virus to its target cell and to avoid infection in subjects at high risk of contagion since there is currently none accepted by COFEPRIS as a prophylactic treatment against hMPV.

Palabras llave : hMPV; respiratory infections; epitopes; protein F; vaccines.

        · resumen en Español     · texto en Español     · Español ( pdf )